Animal Euthanasia Market is valued at US$ 1.50 Bn in 2024 and it is expected to reach US$ 2.68 Bn by 2034, with a CAGR of 6.2% during the forecast period of 2025-2034.
Animal euthanasia involves the humane termination of an animal’s life to prevent unnecessary suffering or control disease spread. Guided by veterinary standards, it ensures rapid unconsciousness with minimal distress and safe carcass handling. The practice is applied across companion animal care, livestock management, wildlife control, and research settings. Growing pet ownership, rising veterinary care costs, and heightened awareness of ethical treatment are driving market expansion. Additionally, disease outbreaks in livestock and poultry increase the demand for humane depopulation methods. Advances in veterinary training, approved drugs, and equipment further support consistent, compassionate euthanasia practices worldwide.
The market is expanding because large-scale, disease-driven euthanasia events highlight the critical role of shelter medicine and emergency protocols, potentially increasing demand for veterinary euthanasia drugs, mobile euthanasia services, and disease-prevention measure. According to the ASPCA, an estimated 920,000 dogs and cats are euthanized annually in U.S. shelters, including about 390,000 dogs and 530,000 cats, mainly due to overpopulation and limited capacity. However, pentobarbital shortages and barbiturate supply shocks are some of the obstacles impeding the growth of the animal euthanasia sector. Over the course of the forecast period, opportunities for the animal euthanasia market will be created by specific growing emphasis on animal welfare programs, in-home end-of-life care, and humane alternatives.
Some of the Key Players in Animal Euthanasia Market:
· Zoetis Inc.
· Boehringer Ingelheim GmbH
· Merck & Co. Inc.
· Elanco
· Vetoquinol SA
· Dechra Pharmaceuticals PLC
· Virbac
· Hikma Pharmaceuticals PLC
· Akorn Animal Health, Inc.
· Piramal Critical Care Inc.
· Others
The animal euthanasia market is segmented by product, animal, route of administration, and end use. By product, the market is segmented into pharmaceuticals, inhalants, and others. pharmaceuticals is further classified into barbiturates, combination drugs, and non-barbiturate anesthetics. By animal, the market is segmented into companion animals, livestock animals, and others. By route of administration, the market is segmented into injectable, inhalants, and others. injectable are further classified into intravenous, intramuscular, and subcutaneous. By end use, the market is segmented into veterinary hospitals and clinics, animal shelters & rescue centers, research laboratories & universities, and others.
In 2024, the pharmaceuticals segment dominated the animal euthanasia market. This leadership is driven by the widespread preference for pharmaceutical agents in veterinary hospitals, clinics, and animal shelters due to their rapid onset of action, reliable outcomes, and minimal stress on animals. Pharmaceuticals have become the preferred choice for both companion and livestock animal euthanasia over mechanical or inhalant methods, supported by established regulatory approvals, broad availability, and extensive veterinary familiarity with these drugs.
The companion animals segment dominated the animal euthanasia market, driven by rising pet ownership, growing pet humanization, and the increasing demand for compassionate end-of-life care. Pet owners are progressively seeking professional veterinary assistance both in-clinic and in-home to ensure a painless and dignified process for their dogs, cats, and other domestic animals. This segment’s commercial strength is further reinforced by deep emotional bonds between owners and pets, higher disposable incomes, and heightened awareness of ethical euthanasia practices, solidifying its leading position in the market.
In 2024, North America dominated the animal euthanasia market, with the United States leading regional growth. This dominance is attributed to advanced veterinary care infrastructure, rising pet ownership, and greater awareness of compassionate end-of-life care. The increasing popularity of in-home euthanasia services highlights the region’s focus on providing humane, accessible, and emotionally supportive options for pet owners.
The Asia-Pacific region is witnessing the fastest growth in the animal euthanasia market. Expanding pet ownership, improved veterinary services, and a growing understanding of humane end-of-life practices are driving this surge. Countries such as China and India are seeing particularly strong demand, fueled by the rapid increase in companion animals and the adoption of ethical pet care standards.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.50 Bn |
|
Revenue Forecast In 2034 |
USD 2.68 Bn |
|
Growth Rate CAGR |
CAGR of 6.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Animal, By Route of Administration, By End Use, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
|
Competitive Landscape |
Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Elanco, Vetoquinol SA, Dechra Pharmaceuticals PLC, Virbac, Hikma Pharmaceuticals PLC, Akorn Animal Health, Inc., and Piramal Critical Care Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Animal Euthanasia Market Snapshot
Chapter 4. Global Animal Euthanasia Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Animal Euthanasia Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Animal Euthanasia Market Industry Trends
Chapter 5. Animal Euthanasia Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Pharmaceuticals
5.2.1.1. Barbiturates
5.2.1.2. Combination Drugs
5.2.1.3. Non-barbiturate anesthetics
5.2.2. Inhalants
5.2.3. Others
Chapter 6. Animal Euthanasia Market Segmentation 2: By Animal, Estimates &
Trend Analysis
6.1. Market Share by Animal, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Animal:
6.2.1. Companion Animals
6.2.2. Livestock Animals
6.2.3. Others
Chapter 7. Animal Euthanasia Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
7.2.1. Injectable
7.2.1.1. Intravenous
7.2.1.2. Intramuscular
7.2.1.3. Subcutaneous
7.2.2. Inhalants
7.2.3. Others
Chapter 8. Animal Euthanasia Market Segmentation 4: By End‑User, Estimates & Trend Analysis
8.1. Market Share by End‑User, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End‑User:
8.2.1. Veterinary Hospitals and Clinics
8.2.2. Animal Shelters & Rescue Centers
8.2.3. Research Laboratories & Universities
8.2.4. Others
Chapter 9. Animal Euthanasia Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Animal Euthanasia Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.2.3. North America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Animal, 2021-2034
9.2.4. North America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. North America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.3. Europe
9.3.1. Europe Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.3.3. Europe Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Animal, 2021-2034
9.3.4. Europe Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Europe Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.4.3. Asia Pacific Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Animal, 2021-2034
9.4.4. Asia Pacific Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Asia Pacific Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.5. Latin America
9.5.1. Latin America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.5.3. Latin America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Animal, 2021-2034
9.5.4. Latin America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Latin America Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Product, 2021-2034
9.6.3. Middle East & Africa Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Animal, 2021-2034
9.6.4. Middle East & Africa Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by Route of Administration, 2021-2034
9.6.5. Middle East & Africa Animal Euthanasia Market Revenue (US$ Mn) Estimates and Forecasts by End‑User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Zoetis Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Boehringer Ingelheim GmbH
10.2.3. Merck & Co. Inc.
10.2.4. Elanco
10.2.5. Vetoquinol SA
10.2.6. Dechra Pharmaceuticals PLC
10.2.7. Virbac
10.2.8. Hikma Pharmaceuticals PLC
10.2.9. Akorn Animal Health, Inc.
10.2.10. Piramal Critical Care Inc.
Animal Euthanasia Market by Product
· Pharmaceuticals
o Barbiturates
o Combination Drugs
o Non-barbiturate anesthetics
· Inhalants
· Others
Animal Euthanasia Market by Animal
· Companion Animals
· Livestock Animals
· Others
Animal Euthanasia Market by Route of Administration
· Injectable
o Intravenous
o Intramuscular
o Subcutaneous
· Inhalants
· Others
Animal Euthanasia Market by End Use
· Veterinary Hospitals and Clinics
· Animal Shelters & Rescue Centers
· Research Laboratories & Universities
· Others
Animal Euthanasia Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here
